Kangfang Biology (09926.HK) completes the issuance of new shares and the issuance of existing shares under a general authorization.

The Zhixin Financial APP reported that Kangfang Biotechnology (09926.HK) has announced that all conditions of the first-level placement agreement have been met, and the completion of the first-level placement was finalized on September 4, 2025. According to the terms and conditions of the first-level placement agreement, a total of 23.55 million shares of first-level placement shares have been placed by the placement agent to no fewer than six underwriters at a placement price of HK$149.54 per share, equivalent to approximately 2.56% of the company's enlarged issued share capital after the issuance and placement of shares following the completion of the first-level placement.